Genetic variants, neurocognitive outcomes, and functional neuroimaging in survivors of childhood acute lymphoblastic leukemia.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
03 07 2023
03 07 2023
Historique:
received:
27
04
2023
revised:
11
05
2023
accepted:
24
05
2023
medline:
5
7
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
ppublish
Résumé
Genetic predispositions may modulate risk for developing neurocognitive late effects in childhood acute lymphoblastic leukemia (ALL) survivors. Long-term ALL survivors (n = 212; mean = 14.3 [SD = 4.77] years; 49% female) treated with chemotherapy completed neurocognitive testing and task-based functional neuroimaging. Based on previous work from our team, genetic variants related to the folate pathway, glucocorticoid regulation, drug metabolism, oxidative stress, and attention were included as predictors of neurocognitive performance, using multivariable models adjusted for age, race, and sex. Subsequent analyses evaluated the impact of these variants on task-based functional neuroimaging. Statistical tests were 2-sided. Survivors exhibited higher rates of impaired attention (20.8%), motor skills (42.2%), visuo-spatial memory (49.3%-58.3%), processing speed (20.1%), and executive function (24.3%-26.1%) relative to population norms (10%; P < .001). Genetic variants implicated in attention deficit phenotypes predicted impaired attention span (synaptosome associated protein 25, F(2,172) = 4.07, P = .019) and motor skills (monoamine oxidase A, F(2,125) = 5.25, P = .007). Visuo-spatial memory and processing speed varied as a function of genetic variants in the folate pathway (methylenetetrahydrofolate reductase [MTHFRrs1801133], F(2,165) = 3.48, P = .033; methylenetetrahydrofolate dehydrogenase 1 [MTHFD1rs2236225], F(2,135) = 3.8, P = .025; respectively). Executive function performance was modulated by genetic variants in the folate pathway (MTHFD1rs2236225, F(2,158) = 3.95, P = .021; MTHFD1rs1950902, F(2,154) = 5.55, P = .005) and glucocorticoid regulation (vitamin D receptor, F(2,158) = 3.29, P = .039; FKBP prolyl isomerase 5, F(2,154) = 5.6, P = .005). Additionally, MTHFD1rs2236225 and FKBP prolyl isomerase 5 were associated with altered brain function during attention and working memory (P < .05; family wise error corrected). Results extend previous findings of genetic risk of neurocognitive impairment following ALL therapy and highlight the importance of examining genetic modulators in relation to neurocognitive deficits.
Sections du résumé
BACKGROUND
Genetic predispositions may modulate risk for developing neurocognitive late effects in childhood acute lymphoblastic leukemia (ALL) survivors.
METHODS
Long-term ALL survivors (n = 212; mean = 14.3 [SD = 4.77] years; 49% female) treated with chemotherapy completed neurocognitive testing and task-based functional neuroimaging. Based on previous work from our team, genetic variants related to the folate pathway, glucocorticoid regulation, drug metabolism, oxidative stress, and attention were included as predictors of neurocognitive performance, using multivariable models adjusted for age, race, and sex. Subsequent analyses evaluated the impact of these variants on task-based functional neuroimaging. Statistical tests were 2-sided.
RESULTS
Survivors exhibited higher rates of impaired attention (20.8%), motor skills (42.2%), visuo-spatial memory (49.3%-58.3%), processing speed (20.1%), and executive function (24.3%-26.1%) relative to population norms (10%; P < .001). Genetic variants implicated in attention deficit phenotypes predicted impaired attention span (synaptosome associated protein 25, F(2,172) = 4.07, P = .019) and motor skills (monoamine oxidase A, F(2,125) = 5.25, P = .007). Visuo-spatial memory and processing speed varied as a function of genetic variants in the folate pathway (methylenetetrahydrofolate reductase [MTHFRrs1801133], F(2,165) = 3.48, P = .033; methylenetetrahydrofolate dehydrogenase 1 [MTHFD1rs2236225], F(2,135) = 3.8, P = .025; respectively). Executive function performance was modulated by genetic variants in the folate pathway (MTHFD1rs2236225, F(2,158) = 3.95, P = .021; MTHFD1rs1950902, F(2,154) = 5.55, P = .005) and glucocorticoid regulation (vitamin D receptor, F(2,158) = 3.29, P = .039; FKBP prolyl isomerase 5, F(2,154) = 5.6, P = .005). Additionally, MTHFD1rs2236225 and FKBP prolyl isomerase 5 were associated with altered brain function during attention and working memory (P < .05; family wise error corrected).
CONCLUSIONS
Results extend previous findings of genetic risk of neurocognitive impairment following ALL therapy and highlight the importance of examining genetic modulators in relation to neurocognitive deficits.
Identifiants
pubmed: 37285328
pii: 7191779
doi: 10.1093/jncics/pkad039
pmc: PMC10317488
pii:
doi:
Substances chimiques
Glucocorticoids
0
Folic Acid
935E97BOY8
Peptidylprolyl Isomerase
EC 5.2.1.8
Tacrolimus Binding Proteins
EC 5.2.1.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH085849
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA225590
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA195547
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Neurobiology (Bp). 1999;7(2):235-46
pubmed: 10591056
J Natl Cancer Inst. 2021 May 4;113(5):588-596
pubmed: 32882041
J Pediatr. 2008 Jan;152(1):101-5
pubmed: 18154909
Dev Psychopathol. 2017 Dec;29(5):1895-1903
pubmed: 29162190
Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):430-3
pubmed: 17427196
BMC Med. 2019 Mar 20;17(1):64
pubmed: 30890171
J Psychiatry Neurosci. 2009 Sep;34(5):361-6
pubmed: 19721846
J Int Neuropsychol Soc. 2014 Jan;20(1):11-9
pubmed: 24103232
Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S186-95
pubmed: 19560279
Psychooncology. 2014 Jun;23(6):692-9
pubmed: 24497266
J Clin Oncol. 2013 Dec 10;31(35):4407-15
pubmed: 24190124
Transl Psychiatry. 2016 Oct 18;6(10):e925
pubmed: 27754486
J Can Acad Child Adolesc Psychiatry. 2015 Winter;24(1):25-32
pubmed: 26336377
Neurochem Res. 2012 Feb;37(2):349-57
pubmed: 21996783
Nature. 1985 Dec 19-1986 Jan 1;318(6047):635-41
pubmed: 2867473
Neuropsychol Rev. 2019 Jun;29(2):190-219
pubmed: 30927148
J Child Neurol. 1996 Mar;11(2):112-5
pubmed: 8881987
Mol Psychiatry. 2000 Jul;5(4):405-9
pubmed: 10889551
J Clin Oncol. 2015 Jul 1;33(19):2205-11
pubmed: 25987702
J Int Neuropsychol Soc. 2004 Mar;10(2):301-3
pubmed: 15012851
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
J Clin Oncol. 2013 Jun 10;31(17):2182-8
pubmed: 23650422
J Clin Oncol. 2011 Feb 10;29(5):551-65
pubmed: 21220611
J Clin Oncol. 2021 Jun 1;39(16):1705-1717
pubmed: 33886368
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1838-49
pubmed: 21844244
N Engl J Med. 2009 Jun 25;360(26):2730-41
pubmed: 19553647
Pediatr Blood Cancer. 2011 Sep;57(3):454-60
pubmed: 21618410
Nat Protoc. 2006;1(2):892-9
pubmed: 17406322
Appl Neuropsychol Adult. 2016;23(1):29-34
pubmed: 26111011
Brain Connect. 2018 Aug;8(6):333-342
pubmed: 29936880
Neurosci Biobehav Rev. 2015 Jun;53:108-20
pubmed: 25857254
Curr Opin Neurobiol. 2009 Dec;19(6):615-20
pubmed: 19896833
Ann Hematol. 2004;83 Suppl 1:S124-6
pubmed: 15124703
J Neurosci. 2010 Jul 21;30(29):9910-8
pubmed: 20660273
Lancet Oncol. 2015 Nov;16(15):1506-1514
pubmed: 26404501
Res Dev Disabil. 2014 Nov 6;36C:338-357
pubmed: 25462494
Mol Psychiatry. 2005 Nov;10(11):998-1005, 973
pubmed: 16088329
Am J Med Genet B Neuropsychiatr Genet. 2003 Jan 1;116B(1):84-9
pubmed: 12497620
J Clin Exp Neuropsychol. 1986 Jun;8(3):219-28
pubmed: 3722348
J Clin Oncol. 2016 Aug 1;34(22):2644-53
pubmed: 27269941
Cancer Res. 2020 Sep 1;80(17):3755-3764
pubmed: 32554749